Tobacco compromises lung function, and COVID-19 primarily
affects the lungs. Smoking tobacco is also a known risk factor for severe
disease from many respiratory infections, including coronaviruses SARS (first
identified in 2003) and MERS-CoV (first documented in June 2012). Smoking also
impairs the immune system and previous studies have established that tobacco
use is linked with poorer outcomes for people with TB and pneumonia.
Evidence indicates that smokers are more likely to suffer
more severe outcomes of COVID-19, such as admission into intensive care units
and death, than never smokers. Furthermore,
severe forms of COVID-19 or deaths due to COVID-19 are more frequent in people
with comorbidities that are related to tobacco use, including COPD, lung cancer
and cardiovascular diseases. There is currently only limited information on
COVID-19 in relation to other tobacco products (e.g. heated tobacco products,
waterpipe, cigars) and electronic nicotine delivery systems (e.g.
e-cigarettes), although these products are thought to play an unfavourable role
in COVID-19 severity.
There is currently limited evidence about the relationship between e-cigarette use and COVID-19. However, existing evidence indicates that electronic nicotine delivery systems (ENDS) and electronic non-nicotine delivery systems (ENNDS), more commonly referred to as e-cigarettes, are harmful and increase the risk of heart disease and lung disorders. Given that the COVID-19 virus affects the respiratory tract, e-cigarette use may increase the risk of infection or severity of outcomes due to COVID-19.
Using smokeless tobacco often involves some hand to mouth
contact. Another risk associated with using smokeless tobacco products,
like chewing tobacco, is that the virus can be spread when the user spits out
the excess saliva produced during the chewing process.
Given the risks to health that tobacco use causes, WHO
recommends quitting tobacco use. Quitting will help your lungs and heart to
work better from the moment you stop. Within 20 minutes of quitting, elevated
heart rate and blood pressure drop. After 12 hours, the carbon monoxide level
in the bloodstream drops to normal. Within 2–12 weeks, circulation improves and
lung function increases. After 1–9 months, coughing and shortness of breath
decrease. Quitting will help to protect your loved ones, especially children,
from exposure to second-hand smoke.
WHO recommends the use of proven interventions such as
toll-free quit lines, mobile text-messaging cessation programmes, and nicotine
replacement therapies (NRTs), among others, for quitting tobacco use.
There is currently insufficient information to confirm any
link between nicotine in the prevention or treatment of COVID-19. WHO urges
researchers, scientists and the media to be cautious about amplifying unproven
claims that tobacco or nicotine could reduce the risk of COVID-19. WHO is
constantly evaluating new research, including that which examines the link
between tobacco use, nicotine use, and COVID-19.